SLX4: A Protein Regulating Insulin Release (G84464)

Target Name: SLX4

NCBI ID: G84464

SLX4

SLX4: A Protein Regulating Insulin Release

SLX4 (KiAA1987) is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Kallikrein-related peptidases (KLK) family, which are a group of enzymes that regulate proteolysis, the breakdown of proteins by enzymes.

SLX4 is known for its role in the regulation of insulin secretion from the pancreas. Insulin is a hormone that is produced by the pancreas in response to changes in blood sugar levels. When blood sugar levels are high, the pancreas releases insulin to help regulate them. However, when blood sugar levels are low, the pancreas does not release insulin.

SLX4 is involved in the regulation of this process by helping to regulate the amount of insulin that is released by the pancreas. It does this by binding to a specific receptor on the surface of the pancreas that is responsible for regulating insulin release. This interaction between SLX4 and the pancreas receptor allows for precise control over insulin release, which is critical for maintaining proper blood sugar levels.

SLX4 is also involved in the regulation of other processes in the body, including cell signaling, inflammation, and metabolism. For example, it has been shown to play a role in the regulation of pain perception and neurogenesis, which are important for maintaining the health and function of the brain and other tissues.

In addition to its role in insulin regulation, SLX4 has also been shown to be a potential drug target. Researchers have identified several potential small molecules that can interact with SLX4 and are being explored as potential therapeutic agents for a variety of diseases, including diabetes, cancer, and neurodegenerative disorders.

One of the most promising of these small molecules is a compound called NX1062, which is a potent inhibitor of SLX4. NX1062 has been shown to block the activity of SLX4 and to reduce insulin release from the pancreas in a variety of cell types and animal models of disease.

Another small molecule that is being investigated as a potential therapeutic agent for SLX4-related diseases is a compound called MK-8628, which is a inhibitor of the protein KLK3. KLK3 is a similar protein to SLX4 that is expressed in many tissues and is involved in the regulation of a variety of processes, including proteolysis and inflammation.

MK-8628 has been shown to be more potent than NX1062 in blocking the activity of KLK3 and has been shown to be effective in animal models of diabetes and other diseases. It is also expected to be a safe and effective therapeutic agent, as it is currently being tested in a variety of clinical trials.

In conclusion, SLX4 is a protein that is involved in the regulation of insulin release from the pancreas, as well as many other processes in the body. It is a potential drug target and has been shown to be involved in a variety of diseases, including diabetes and neurodegenerative disorders. Further research is needed to fully understand the role of SLX4 and to develop effective therapies for these diseases.

Protein Name: SLX4 Structure-specific Endonuclease Subunit

Functions: Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure-specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81-EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks

The "SLX4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLX4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets